Veradermics (MANE) Cash & Equivalents (2024 - 2026)

Veradermics has reported Cash & Equivalents for 3 years, with the latest figure at $168.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents changed N/A year-over-year to $168.4 million; the trailing twelve-month figure through Mar 2026 stood at $168.4 million (changed N/A YoY), and the FY2025 full-year result was $21.8 million, down 59.0% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $168.4 million, up from $21.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $168.4 million in Q1 2026, with the low at $21.8 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $81.1 million across 3 years, with a median of $53.1 million in 2024.
• The largest YoY upside for Cash & Equivalents was 59.0% in 2025 against a maximum downside of 59.0% in 2025.
• Veradermics' Cash & Equivalents stood at $53.1 million in 2024, then sank by 59.0% to $21.8 million in 2025, then surged by 673.74% to $168.4 million in 2026.
• The last three Cash & Equivalents figures came in at $168.4 million (Q1 2026), $21.8 million (Q4 2025), and $53.1 million (Q4 2024), per Business Quant data.